CHKA

Choline kinase alpha · P35790 · CHKA on Sugi Atlas →

23,462 patent compounds predicted against CHKA, 12,426 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Bromide (SCHEMBL612817)	0.61	19/20
SCHEMBL110133	1.00	14/20
Hydrochloric Acid (SCHEMBL580650)	0.96	14/20
Fluoride Ion (SCHEMBL126023)	0.93	14/20
Fluoride Ion (SCHEMBL126024)	0.93	14/20
Fluoride Ion (SCHEMBL125568)	0.68	14/20
Fluoride Ion (SCHEMBL125569)	0.68	14/20
Hydrochloric Acid (SCHEMBL262371)	0.56	13/20
SCHEMBL151521	0.69	11/20
SCHEMBL904053	0.57	11/20
Benzyl Viologen (SCHEMBL599497)	0.57	11/20
SCHEMBL786767	0.46	11/20
SCHEMBL547278	0.54	10/20
SCHEMBL112580	0.50	10/20
SCHEMBL560091	0.45	9/20
SCHEMBL560092	0.45	9/20
SCHEMBL348581	0.62	8/20
Bromide (SCHEMBL365151)	0.61	8/20
SCHEMBL367939	0.61	8/20
SCHEMBL300433	0.56	8/20

Clinical trials — most relevant to CHKA by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Nerve Growth Factor Encapsulated With 2-methacryloyloxyethyl Phosphorylcholine Nanocapsules in the Treatment of Amyotrophic Lateral Sclerosis	PHASE2/PHASE3	NOT_YET_RECRUITING
Gemcitabine Hydrochloride and Oxaliplatin or Observation in Treating Patients With Biliary Tract Cancer That Has Been Removed by Surgery	PHASE3	COMPLETED
Cholinergic Integrity in Down Syndrome in Association With Aging, Alzheimer's Disease Pathology, and Cognition	PHASE2	RECRUITING
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy	PHASE2	COMPLETED
Biological Effects of Quercetin in COPD Phase II	PHASE2	UNKNOWN
Nefiracetam in the Treatment of Alzheimer's Disease	PHASE2	COMPLETED
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients	PHASE1/PHASE2	WITHDRAWN
Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer	PHASE2	COMPLETED
Fibrates in Pediatric Cholestasis	PHASE2	COMPLETED
Phase II Study of Simvastatin Plus Irinotecan, Fluorouracil, and Leucovorin(FOLFIRI) for Metastatic CRC	PHASE2	COMPLETED
Choline Effects - Pre-symptomatic AD	PHASE1	COMPLETED
Gene Therapy for Alzheimer's Disease Clinical Trial	PHASE1	COMPLETED
Role of Citicoline in Treatment of Neonates With Hypoxic Ischemic Encephalopathy	PHASE1	RECRUITING
Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer.	PHASE1	COMPLETED
Analysis of Tissues From Patients in Trial of Myo-Inositol to Prevent Lung Cancer	PHASE1	COMPLETED
Egg Intake, Metabolic Outcomes and Choline Levels	nan	RECRUITING
Choline to Improve Malnutrition and Enhance Cognition	nan	RECRUITING
Choline Dose Ranging in Postmenopausal Women	nan	COMPLETED
Striatal and Extra-Striatal Cholinergic Terminal Density in LRRK2-PD Mutation	nan	RECRUITING
Utilizing Non-Invasive Fibroscan® Technology to Identify Genetic Markers for Fatty Liver Progression	nan	COMPLETED
Free Fatty Acid Induced Insulin Resistance	nan	COMPLETED
Choline and Brain Functioning in Postmenopausal Women	nan	COMPLETED
Epidemiology of Atherosclerosis	nan	COMPLETED
Evaluation of Plasma Sphingosine-1-Phosphate as A Diagnostic and Prognostic Biomarkers of Community-Acquired Pneumonia	nan	UNKNOWN
Rostock International Parkinson's Disease Study (ROPAD)	nan	COMPLETED
A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study	nan	COMPLETED
Impact Of Choline in Patients With NAFLD	nan	UNKNOWN
Immune Cell Response to Stimuli	nan	RECRUITING
Effects of Colesevelam HCl On Bile Acid Kinetics	nan	COMPLETED
Effect of Esterogen Receptor Modulator on Gene in Bipolar Diseas	nan	NOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a CHKA binder may also engage these)

Protein	Name	Similarity
Q01134	—	0.992	Q01134 →
O54804	—	0.984	O54804 →
D3Z7P3	—	0.955	D3Z7P3 →
Q4R766	—	0.954	Q4R766 →
GLS	Glutaminase kidney isoform, mitochondrial	0.951	landscape →
CHKB	Choline/ethanolamine kinase	0.951	landscape →
ABHD12	Lysophosphatidylserine lipase ABHD12	0.950	landscape →
Q08DW9	—	0.950	Q08DW9 →
Q5ZIN0	—	0.947	Q5ZIN0 →
P13264	—	0.946	P13264 →
METTL16	RNA N(6)-adenosine-methyltransferase METTL16	0.941	landscape →
Q6AYT7	—	0.940	Q6AYT7 →
B0VX69	—	0.940	B0VX69 →
Q8WWQ2	—	0.940	Q8WWQ2 →
Q86XW9	—	0.937	Q86XW9 →
Q8NBA8	—	0.937	Q8NBA8 →
Q9H1A3	—	0.936	Q9H1A3 →
Q7Z6J6	—	0.936	Q7Z6J6 →
Q6DN14	—	0.935	Q6DN14 →
Q99LR1	—	0.934	Q99LR1 →
DNMT3A	DNA (cytosine-5)-methyltransferase 3A	0.934	landscape →
Q5NVN7	—	0.934	Q5NVN7 →
A0A2R8QFQ6	—	0.934	A0A2R8QFQ6 →
CDC16	Cell division cycle protein 16 homolog	0.934	landscape →
A6QLH5	—	0.934	A6QLH5 →
Q28D01	—	0.933	Q28D01 →
Q09LZ8	—	0.933	Q09LZ8 →
Q8C460	—	0.933	Q8C460 →
Q9EPL4	—	0.933	Q9EPL4 →
Q8N5X7	—	0.933	Q8N5X7 →